Jubilant Pharmova reported a 41.40% increase in total revenue for the June 21 quarter on a consolidated basis to Rs1,634.65cr. On a sequential basis, revenue increased 3.47% from revenue of Rs1,579.78cr on March 21. COVID 2.0 had a limited impact on revenue for the June 21 quarter.
The pharmaceuticals vertical grew 40% year-on-year while contract research and development (CDMO) also hit the streets with 50% year-on-year growth. The life sciences segment has been separated and presented as part of the discontinued operations.
Net profit for the June 21 quarter increased 82.43% to Rs160.56cr on an annual basis, but on a sequential basis the PAT was down -24.94% due to the impact of COVID 2.0. The increase in EBITDA stems from the pharmaceutical business which saw EBITDA increase by almost 170% year-on-year.
CDMO’s EBITDA also more than doubled year-on-year. Net margins at 9.82% for the June 21 quarter are significantly higher than 7.61% in the June 20 quarter but below 13.54% in the sequential March 21 quarter. However, the previous figures include discontinued operations.
June 21 financial highlights compared year-over-year and sequentially
|Rs in crore||June-21||June 20||YEAR||Mar-21||QOQ|
|Total income (Rs cr)||â¹ 1,634.65||1,156.07||41.40%||â¹ 1,579.78||3.47%|
|Net profit (Rs cr)||160.56||88.01||82.43%||213 213.90||-24.94%|
|Diluted EPS (Rs)||10.09||5.53||13.43|